Stockholders Approve Reverse Split, Double Authorized Shares for Galera Therapeutics

summarizeSummary

Galera Therapeutics stockholders approved a reverse stock split (1:75 to 1:200) and doubled authorized shares to 400 million, critical steps for the company's announced merger and continued operations.

check_boxKey Events

• Reverse Stock Split Approved

  Stockholders approved an amendment to the Charter to effect a reverse stock split at a ratio between 1:75 and 1:200, if and when determined by the Board. This is a critical step for maintaining exchange listing and facilitating the recently announced merger.

• Authorized Shares Doubled

  The number of authorized shares of common stock was increased from 200 million to 400 million, providing significant headroom for future capital raises or merger-related share issuance. This follows the PRE 14A and DEF 14A filings proposing this increase.

• Shareholder Written Consent Right Approved

  Stockholders approved an amendment to the Charter to permit stockholders to act by written consent in lieu of a meeting, enhancing shareholder governance.

auto_awesomeAnalysis

This 8-K reports the definitive approval by stockholders of several critical proposals, including a reverse stock split and a substantial increase in authorized shares. These actions are essential for Galera Therapeutics, which recently announced a merger with Obsidian Therapeutics and has a "going concern" warning. The reverse stock split is likely necessary to meet exchange listing requirements, while the increased authorized shares provide the company with significant flexibility for future capital raises or to issue shares related to the merger. The approval of these measures, while potentially dilutive, enables the company to proceed with its strategic restructuring and merger.